Earnings call transcripts

Management framed the quarter as on plan, with strong liquidity and progress toward A-sample development, while commercialization remains several milestones away.

Management framed growth as broad-based EVO adoption overcoming currency and COVID disruptions, while stressing U.S. launch investment and refusing to quantify U.S. growth.

Management framed the quarter as resilient but stressed that 2022 lockdowns pose a deeper, less predictable operating shock than 2020.

Management framed the quarter as demand-led growth strong enough to raise the outlook, while stressing that supply capacity—not demand—would limit near-term GLP-1 sales.

Management framed the quarter around strong global ICL demand and a newly opened U.S. growth opportunity, while highlighting China lockdowns and launch spending timing. 600 U.S.

Management framed 2022 as a deliberate reset, prioritizing channel quality and transformation before expecting growth to resume in the second half.

Management framed the quarter as a volume-led recovery, while stressing that pandemic restrictions still constrain events and near-term visibility.

Management framed 2022 as continued GLP-1-led growth, with obesity demand constrained by Wegovy supply and investment priorities weighing on margins. U.S.

Management framed 2022 around deepening merchant relationships and building capabilities, with fulfillment moving from experimentation into a more capital-intensive build phase.

Management framed 2022 as a capacity-building and brand-investment year, with non-U.S. markets leading growth while U.S. approval remains uncertain.

Management framed results as broad-based, GLP-1-led growth, while stressing that 2021 was exceptional and that several temporary factors complicate 2022 comparisons.

Management framed normalization from pandemic e-commerce peaks as a return to steadier growth, while emphasizing broader omnichannel reach and merchant tools.